The invention relates to Inter-alpha inhibitor proteins (IαIp). The invention further relates to processes for purification of IαIp compositions and their use for treatment of human diseases such as sepsis and septic shock, rheumatoid arthritis, cancer and infectious diseases.
|
0. 26. A method of treating sepsis or septic shock in a human in need thereof comprising administering to the human more than one dose of a pharmaceutical composition comprising 1 to 50 milligrams (mg) inter-alpha inhibitor proteins (IαIps) per kilogram (kg) body weight of the human, wherein the IαIps comprise 5% to 95% by weight of the composition and comprise a mixture of 60% to 80% inter-alpha inhibitor (IαI) and 40% to 20% pre-alpha inhibitor (PαI), the composition is suitable for administration to the human, and each dose of the composition is administered every 4 to 120 hours from about 1 to about 6 times per day.
0. 1. A process for producing a blood plasma-derived IαIp composition comprising a mixture of inter-alpha inhibitor protein (IαI) and pre-alpha protein (PαI), wherein the IαI and the PαI are present in said mixture in a physiological proportion, the process comprising:
isolating from blood plasma a plasma fraction containing IαI and PαI, wherein the IαI and PαI are present in a physiological proportion; and
purifying the plasma fraction to obtain an IαIp composition with a purity of IαIp ranging from about 85% to about 100% pure, wherein the purifying comprises hydroxylapatite chromatography.
0. 2. The process of
0. 3. The process of
0. 4. The process of
0. 5. The process of
0. 6. The process of
0. 7. The process of
0. 8. The process of
0. 9. The process of
0. 10. The process of
purifying the plasma fraction; virus inactivating the plasma fraction and/or the purified IαIp; the addition of stabilizers; pasteurization of the purified IαIp;
or anion-exchange chromatography of the purified IαIp.
0. 11. The process of
0. 12. The process of
0. 13. A composition of IαIp comprising a mixture of inter-alpha inhibitor protein (IαI) and pre-alpha protein (PαI), wherein the IαI and the PαI are present in said mixture in a physiological proportion and: have a high trypsin inhibitory specific activity between about 1000 to about 2000 IU/mg; have a half life of greater than one hour; comprise a light chain of inter-alpha inhibitor protein associated with at least one of three heavy chains H1, H2 and H3; or comprise a light chain of inter-alpha inhibitor protein associated with at least one of three heavy chains H1, H2, H3 and H4.
0. 14. The composition of
0. 15. The composition of
0. 16. The composition of
0. 17. A composition of IαIp comprising a mixture of inter-alpha inhibitor protein (IαI) and pre-alpha protein (PαI), wherein the IαI and the PαI are present in said mixture in a physiological proportion, said composition having been prepared by the process according to
0. 18. The composition of
0. 19. The composition of
0. 20. A pharmaceutical composition comprising a therapeutically effective amount of the composition of
0. 21. A method of treating an inflammation related disorder comprising administering to a subject in need thereof a therapeutically effective amount of the composition of
0. 22. The method of
0. 23. A method of treating an acute inflammatory disease, sepsis, septic shock, rheumatoid arthritis, meningitis, Crohn's Disease, chronic obstructed pulmonary disease and rhinitis in a subject, comprising:
(a) determining the pre-treatment level of one or more of the following levels in a subject:
(i) the level of IαI;
(ii) the level of PαI;
(iii) the level of IαIp;
(iv) the level of H3;
(v) the level of H4;
(vi) the level of H1;
(vii) the level of H2; and
(viii) the level of LC; and
(b) administering a therapeutically effective amount of the composition of
0. 24. A method of monitoring the progress of a subject being treated with an IαIp therapy, comprising:
(a) determining the pre-treatment level of one or more of the following levels, in a subject:
(i) the level of IαI;
(ii) the level of PαI;
(iii) the level of IαIp;
(iv) the level of H3;
(v) the level of H4;
(vi) the level of H1;
(vii) the level of H2; and
(viii) the level of LC;
(b) administering a therapeutically effective amount of the composition of
(c) determining the level of one or more of the levels in the subject after an initial period of treatment with the composition,
wherein an increase of the level in the subject following treatment with the composition indicates that the subject is likely to have a favorable clinical response to treatment with IαIp.
0. 25. A kit comprising a composition according to
0. 27. The method of claim 26, wherein said IαI and PαI comprise a light chain (L) associated with at least one heavy chain selected from H1, H2, H3, and H4.
0. 28. The method of claim 27, wherein the composition has a high trypsin inhibitory specific activity of 1000 to 2000 IU/mg.
0. 29. The method of claim 28, wherein the trypsin inhibitory specific activity of said composition is 1400 to 2000 IU/mg.
0. 30. The method of claim 26, wherein the composition has a half-life of greater than one hour.
0. 31. The method of claim 30, wherein the composition has a half-life of at least 5 hours.
0. 32. The method of claim 31, wherein the composition has a half-life of at least 10 hours.
0. 33. The method of claim 26, wherein the IαI and PαI present in said composition have an apparent molecular weight of 60,000 to 280,000 Da.
0. 34. The method of 26 further comprising, prior to said administering, determining the pre-treatment level of one or more of the following IαIps in the human: IαI, PαI, H3, H4, H1, H2, and LC.
0. 35. The method of claim 34 further comprising determining the level of one or more of IαI, PαI, H3, H4, H1, H2, and LC in the human after an initial period of treatment with the composition.
0. 36. The method of claim 26, wherein the composition further comprises a stabilizer.
0. 37. The method of claim 26, wherein the composition is administered as a tablet, capsule, or injectable.
0. 38. The method of claim 26, wherein the composition is administered by intravenous infusion.
0. 39. The method of claim 26, wherein the composition is administered at least twice.
0. 40. The method of claim 26, wherein the composition is administered until symptoms of the sepsis or septic shock improve.
|
Radioiodination of Protein and Determination of IαIp Half-Life
Purified IαIp was radioiodinated with Na125I (Amersham, Arlington Heights, Ill.) using 1,3,4,6-tetrachloro-3a-6a-diphenyl glycoluril (IODO-GEN iodination reagent; Pierce, Rockford, Ill.). The unincorporated 125I was removed by applying the reaction mixture to an Excellulose GF-5 desalting column (Pierce). Radioactivity was determined in a gamma counter (Pharmacia-LKB, Piscataway, N.J.). At 12 h after CLP or sham operation, the animals were anesthetized with isoflurane inhalation. A steady state of sedation was maintained with a subsequent intravenous injection of sodium pentobarbital (˜30 mg/kg BW). Polyethylene-50 catheters were placed in the right jugular vein and left femoral artery, and a bolus injection of 125I-labeled IαIp (˜500,000 cpm/rat) was administered through the jugular cannula. The remaining radioactivity in the syringe was measured with a gamma counter, and the radioactivity counts were subtracted from the initial preinjection counts to determine the net injected radioactivity. Blood samples were collected immediately after the injection and then every 2 h for a period of 8 h for determining the half-life (t1/2) of 125I-IαIp in the circulation. The radioactivity (cpm) in each sample was measured with a gamma counter. The t1/2 was calculated according to Wu R, Zhou M, Cui X, et al: Ghrelin clearance is reduced at the late stage of polymicrobial sepsis. Int J Mol Med. 2003; 12:777-782.
Survival Study
CLP was performed as described above. At 1, 5, 10 or 10 and 20 h after CLP, human IαIp concentrate (30 mg/kg BW) or vehicle (normal saline, 1.5 ml/rat, at 1 h after CLP or 10 and 20 h after CLP) was infused intravenously. At 20 h after CLP, the necrotic cecum was excised and the abdominal cavity was washed twice by using 40 ml of warm, sterilized normal saline solution. The abdominal incision then was closed in layers. The procedure of cecal excision in CLP animals was performed to mimic the clinical situation in which septic focus should be removed whenever possible. The animals then were allowed food and water ad libitum and were monitored for 10 days to record survival.
Statistical Analysis
Results are expressed as means ±SE. One-way analysis of variance (ANOVA) and Tukey's test were used to compare different groups of experimental animals. The survival rate was estimated by Kaplan-Meier method and compared by the log-rank test. Differences in values were considered significant if P<0.05. 9
Alterations in Bikunin mRNA Expression after CLP
Bikunin is an active part of IαIp. The liver is the major source of bikunin. Therefore, we chose bikunin mRNA expression in the liver to reflect the production of IαIp. As shown in
Alterations in t1/2 of 125I-IαIp after CLP
Half-life of IαIp was estimated by measuring the changes of blood levels of radioactive labeled IαIp injected at 12 h after the onset of sepsis. As indicated in
Effects of IαIp on Survival Rate
The survival rate after CLP and cecal excision with single time vehicle administration (at 1 h after CLP) was 75% at day 2 and decreased to 50% at days 5-10
Sepsis is a clinical syndrome characterized by systemic inflammation, coagulopathy, respiratory failure, myocardial dysfunction, renal insufficiency, and neurocognitive defects. It is generally assumed that this syndrome results from an excessive triggering of endogenous inflammatory mediators by the invading microorganisms. These mediators include substances released by activated monocytes, macrophages, endothelial cells and neutrophils such as cytokines, reactive oxygen species and proteases. In severe inflammatory response, various blood and tissue cells, including polymorphonuclear granulocytes, release lysosomal proteinases extracellularly and into the circulation. Such proteases as well as normally intracellular oxidizing agents produced during phagocytosis, can trigger tissue and organ damage and enhance the nonspecific proteolysis of plasma clotting and complement factors. The release of neutrophil proteinases, especially human leukocyte elastase, has been implicated in the progress of complications in subjects with sepsis. Their plasma levels are in close correlation with the severity of infection-induced inflammation and highly predictive of forthcoming organ failure.
During septic shock in humans, in addition to elevated activities of proteases, decreased plasma levels of IαIp have been reported. Subjects with severely decreased concentrations of IαIp have a higher mortality rate. Our results indicate that the gene expression of bikunin in the liver is significantly lower in the CLP animals than in the sham-operated animals. The expression of mRNA related to proteins in the inter-alpha-inhibitor family has been examined in various tissues in primates, pigs, and rodents. These studies indicate the genes which are the source of all members of the IαIp family are primarily transcribed in the liver. Our results also show the gene expression of bikunin in other organs (i.e., intestine and kidneys) was not significantly altered at 5 or 20 h after CLP as compared to the shams (data not shown).
The significant downregulation observed only in the liver at 20 h after CLP suggests that this organ might be an important source of IαIp and furthermore, in late stages of sepsis, bikunin gene expression in the liver is significantly decreased. Therapeutically, bikunin has been reported to have beneficial effects in humans as a prophylactic treatment to prevent pancreatitis after gastrectomy or to attenuate organ injury after cardiac surgery. Studies that examined the effects of bikunin in an acute canine model of lethal E. coli bacteremia showed similar results with an improvement in hemodynamic variables and normalization of cardiac output and mean arterial pressure. Because the plasma half-life of bikunin is very short (approximately 10 min), it appears important to prolong the half-life of bikunin to maintain the sustained beneficial effects of this agent. Our results show that the half-life of IαIp in sham-operated animals is 5.6 h. When we injected radioactive labeled IαIp at 12 h after the onset of sepsis, we found the half-life of IαIp was prolonged to 11.8 h. These results indicate that IαIp clearance was significantly decreased during sepsis. However, even with decreased clearance the plasma levels of IαIp remain significantly lower in septic subjects. Our previous study has shown that administration of low purity IαIp early after the onset of sepsis (i.e., 1 h post-CLP) maintained cardiac output and systemic oxygen delivery and increased systemic oxygen consumption and systemic oxygen extraction ratio. Moreover, IαIp downregulated TNF-a production and attenuated hepatocellular injury and lactic acidosis at 20 h after CLP. In addition, IαIp administration at 1 h after the onset of sepsis improved survival in septic animals.
Human IαIp proteins were isolated as a by-product of industrial scale plasma fractionation. The isolation method highly, simultaneously enriches the major plasma form of bikunin-containing proteins (IαI and PαI). Thus, in this preparation, a physiologic composition of plasma IαIp is obtained. The results of the mortality study performed indicate that administration of IαIp at 1 h after CLP improved the survival rate from 50% to 92% at 10 days after CLP and cecal excision. Although administration of human IαIp at 5 or 10 h after CLP improved the survival rate to 64% and 73% respectively, these improvements were not statistically significant.
Administration of human IαIp at 10 and 20 h after CLP, however, significantly improved the survival rate from 44% to 81%. Thus, IαIp appear to be a useful adjunct for improving survival during the progression of polymicrobial sepsis. In summary, bikunin gene expression in the liver decreased during sepsis and the half-life of IαIp increased from 5.6±0.3 h to 11.8±2.7 h, suggesting downregulation of bikunin in sepsis despite a decrease clearance. Administration of IαIp at 1 h after CLP improved the survival rate from 50% to 92%, whereas there was no significant improvement when IαIp was administrated at 5 or 10 h after CLP. However, double injection of IαIp at 10 and 20 h after CLP increased the survival rate from 44% to 81%. Delayed but repeated administration of human IαIp improve survival after CLP.
After application of dialyzed or ultra/diafiltrated eluate after solid-phase extraction with DEAF Sephadex A50, weakly bound components are eluted from DEAE-Sepharose FF column with 0.005 M sodium citrate/0.0055 M sodium phosphate buffer, pH 6.0 containing 0.28 M sodium chloride (described in Hoffer et al., Journal of Chromatography B 669 (1995) 187-196). In the previous step, the column was washed with 0.005 M sodium citrate/0.0055 M sodium phosphate buffer, pH 6.0, containing 0.20 M sodium chloride.
After dialysis or ultrafiltration/diafiltration (UF/DF) against 0.005 M sodium phosphate buffer pH 7.0, the eluate was applied to hydroxylapatite column. The IαIp proteins do not bind to the column and are collected as flow through fraction. The contaminating proteins, mainly FII, FVII and FX, can be eluted using a gradient with an increasing concentration of sodium phosphate buffer. The IαI/PαI fraction contains more than 90% of target proteins, mainly IαI and PαI.
Unbound proteins from Heparin Sepharose affinity chromatography (L. Hoffer et al., J. of Chromatography B), are applied to a DEAE-Sepharose FF anion-exchange column. After washing the column with a minimum of three column volumes of 0.005 M phosphate buffer, pH 7.0, IαIp/PαI containing fractions were eluted with 0.005 M phosphate buffer, pH 7.0, containing 0.55 M sodium chloride (elution buffer). The eluate contains about 30-40% IαI/PαI. After dialysis or ultrafiltration/diafiltration (UF/DF) against 0.005 M sodium phosphate buffer, pH 7.0, the eluate from DEAE Sepharose EF was applied to a hydroxylapatite column. The IαI/PαI do not bind to the column and are collected as a flow-through fraction. The contaminating proteins, mainly FII and FX can be eluted using a gradient with increasing concentration of sodium phosphate buffer. The purified IαI/PαI fraction contains more than 90% of the target proteins
Eluant from a solid-phase extraction of cryopoor plasma on DEAE-Sephadex A50 (L. Hoffer et al., J. of Chromatography B) or Q-Sephadex A50 (D. Josic et al., Thrombosis Research, cf. above) was applied to a DEAC-CIM tube monolith with a column volume of 80 mL (cf. K. Branovic et al., J of Chromatography A, 903 (2000) 21-32). The unbound fraction (flow-through) was collected. The column was subsequently washed with three column volume of 0.02 M Tris-HCl, pH 7.4 (equilibration buffer). Bound proteins were eluted in first step with 0.02 M Tris-HCl, pH 7.4, containing 0.35 Mol/L sodium chloride (Eluate 1) and in a second step with 0.02 M Tris-HCl, pH 7.4, containing 0.55 M sodium chloride (Elution 2). IαI/PαI are found in flow-through fractions and Eluate 1. Flow-through fractions contain about 35-45% IαI/PαI. The amount of these target proteins in Eluate 1 is between 20-30%. Fractions containing IαI/PαI were subjected to dialyses or ultrafiltration/diafiltration (UF/DF) against 0.005 M sodium phosphate buffer, pH 7 and applied to a hydroxylapatite column. IαIp do not bind to the column and are collected as a flow-through fraction. The flow-through fraction contains more than 90% of IαI/PαI.
Polymicrobial sepsis was induced by cecal ligation and puncture (CLP) in male Sprague-Dawley rats. Animals were fasted overnight before CLP was performed but were allowed water ad libitum. At the time of the experiment, the rats were anesthetized by methylflurane inhalation, and a 2-cm ventral midline incision was performed. The caecum was exposed, ligated just distally to the ileocecal valve to avoid intestinal obstruction, punctured twice with an 18-gauge needle, squeezed gently to force out a small amount of feces, and then returned to the abdominal cavity. The abdominal incision was closed in layers, and the animals received 30 mL/kg body weight normal saline solution subcutaneously immediately after CLP as a fluid resuscitation. Two groups of rats with n=12 per group were used in this experiment. The treatment group received highly purified IαIp at 10 and 20 hrs after CLP at 30 mg/kg bodyweight. The control group received saline. At 20 hr after CLP, the necrotic caecum was excised and the abdominal cavity washed twice by using 40 mL of warm, sterile normal saline solution. The abdominal incision was then closed in layers. The procedure of cecal excision in CLP animals was performed to mimic the clinical situation in which the septic focus is removed. The experimental animals were allowed food ad libitum and monitored for 10 days to record the time of death for the non-survivors. A log-rank test was employed for comparison of mortality rates among different groups of animals and p values were determined by Kaplan-Meier method. A significant increase in survival was observed in the treatment group compared to the saline control group (81.3% of the animals in the treatment group survived vs. 44% in the control group (p value=0.0293)), suggesting that the highly purified IαIp is biologically active and effective in reducing the sepsis-related death in septic animals. Results are shown in
TABLE 1
Comparison of the specific inhibitory activity of IαIp
Protein
IαIp
IαIp
Specific Inh.
IαIp preparation
conc.
conc.
purity
Activity
Purified from
[mg/mL]
[mg/mL]
[%]
[TIU/mg IαIp]
Cryoprecipitate
7.30
5.10
69.86%
1412 ± 47.52
Cryopoor plasma
17.30
17.00
98.27%
1409 ± 42.50
TIU = Trypsin inhibitory unit; mean ± SD from three independent experiments.
Specific inhibitory activity of the highly purified IαIp (from cryo-poor plasma) was calculated and compared with IαIp purified from the cryoprecipitate, a side-fraction of fVIII production. The biological activity of IαIp was measured in a trypsin inhibition assay using the chromogenic substrate L-BAPA (N(alpha)-Benzoyl-L-arginine-4-nitroanilide hydrochloride (Fluka Chemicals). This assay is based on the ability of IαIp to inhibit the hydrolysis of L-BAPA. Inhibition can be monitored by a decrease in the rate of Δ absorbance/minute at 410 nm. Total protein concentration was quantitatively measured by the BioRad protein assay and IαIp concentrations were measured by a competitive ELISA using MAb 69.31 as described in Lim et al, J. of Infectious Diseases, 2003). There was no significant difference in the specific trypsin inhibitory activity between IαIp preparations purified from cryo-poor plasma and cryoprecipitate (p value=0.939), suggesting that IαIp in both fractions had comparable biological activity.
The “washing fraction” from the chromatographic purification of clotting factor FIX on DEAF-Sepharose FF (Josic et al. Journal of Chromatography, citated above). This fraction can be eluted with a 0.01-0.1 M sodium citrate/0.005-0.1 M sodium phosphate buffer, pH 6.0 containing 0.25 M sodium chloride. The IαI and PαI are the main components in this fraction. The FIX containing fraction can be eluted from DEAE Sepharose FF column with a 0.01-0.1 M sodium citrate/0.005-0.1 M sodium phosphate buffer, pH 6.0 containing 0.3-0.6 M sodium chloride in the next step. This fraction also contains other vitamin K dependent clotting factors such as clotting factor II (FII), clotting factor X (FX), lower amounts of clotting factor VII (FVII) together with residual amounts of IαIp. After dialysis to reduce osmolarity and salt concentration, the residual IαIp in the FIX fraction can be recovered by affinity chromatography on immobilized heparin and step elution in buffers with increasing salt concentration and osmolality. Fractions from an early elution step in the wash buffer contain over 80% IαIp with very low FIX contamination. Elution of FIX occurs at a later step in a buffer with higher salt concentration and osmolality. There is also a flow through fraction that does not bind to heparin, is free of FIX and contains a mixture of IαIp (30-40%), vitamin K-dependent clotting factors, and the solvent/detergent (S/D) used for virus inactivation. The S/D can be removed in an additional chromatographic step of DEAE-Sepharose FF.
IαIp containing fractions collected from DEAE-Sepharose, immobilized heparin or the flow through from heparin can be further purified individually or as a pool by hydroxylapatite chromatography. Using either approach, the final preparation contains more than 90% ITI.
The concentrate purified using these protocols contains more than 90% IαI/PαI. It has been virus inactivated by solvent/detergent treatment. Terminal heating in final container with or without use of stabilizers for more than 30 minutes or pasteurization at 55-65° C. in the presence of stabilizers can be introduced as a second virus inactivation step without significant loss of activity.
The resulting concentrate containing more than 90% IαI/PαI can be virus inactivated with S/D treatment or as a second inactivation step, terminal heating of the purified proteins with or without stabilizers for 30 minutes or alternatively, pasteurization at 55-65° C. in the presence of stabilizers.
A Strong Anion-Exchange Fraction
Instead of the eluate after solid-phase extraction with weak anion-exchanger DEAE Sephadex A50) an eluate after solid phase extraction with a strong anion-exchanger Q Sephadex A50 can be used. Conditions for elution are described in German patent DE 4342132C1. A mixture of IαI and PαI do not bind or only weakly binds to the monolithic anion-exchange support DEAE-CIM. Other proteins such as clotting factors FII, FVII, FIX and FX, clotting inhibitors PC, PS and PZ, adhesion protein vitronectin and protease FSAP are eluted in separate fractions. Further separations of the remaining contaminants can be achieved in the next step using hydroxylapatite chromatography.
A Monolith Chromatographic Fraction
A DEAE CIM monolith (membrane) can be used for chromatographic separation in FIX purification instead of DEAE Sepharose FF or other particle-based anion exchanger (See DE 4342132C1). Surprisingly, IαI and PαI did not bind or bound only weakly to the monolithic support. Other proteins, such as FIX, vitronectin and FII, FVII (low amount) and FX were eluted as separate fractions. The proteolytic activity, coming mainly from Factor VII Activating Protease (FSAP) (J. Roemisch, Biological Chemistry 383 (2002) 1119-1124) was also completely separated in this purification step. Further separation of the remaining contaminants from IαI/PαI containing fraction(s), namely traces of vitamin K dependant clotting factors FII, FVII and FX were achieved in the next step using hydroxylapatite chromatography.
All publications and patent documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication or patent document were so individually denoted. Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991).
The contents of all references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated herein in their entireties by reference.
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended with be encompassed by the following claims.
Josic, Djuro, Lim, Yow-Pin, Hixson, Douglas C.
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
4839298, | Oct 17 1985 | Akzo N.V. | Virus inactivating diluents used in immunoassays |
5166133, | Apr 17 1991 | Chiron Corporation | Method for inhibing adhesion of white blood cells to endothelial cells |
5777081, | Oct 18 1993 | THE LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES; L ESTABLISSEMENT FRANCAIS DU SANG FRENCH BLOOD BANK | Process for producing an inter-alpha-trypsin inhibitor concentrate for therapeutic use and concentrate thus obtained |
5948894, | Dec 18 1989 | BAC IP B V | Immunoadsorbent reagents |
6069236, | Jun 14 1993 | THE LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES; L ESTABLISSEMENT FRANCAIS DU SANG FRENCH BLOOD BANK | Immunoglobulin G concentrate for therapeutic use and process for producing said concentrate |
6313091, | Jul 19 1996 | New York University | Pharmaceutical compositions containing TSG-6 for treating inflammatory diseases and cancer-related pathologies and method |
6489128, | Jan 24 2000 | Rhode Island Hospital, A LifeSpan Partner | Methods for detecting cancer of the central nervous system |
6660482, | Feb 28 2000 | Rhode Island Hospital, A LifeSpan Partner | Inter-alpha-trypsin inhibitor as a marker for sepsis |
6673908, | Feb 22 1999 | NUVELO, INC | Tumor necrosis factor receptor 2 |
7932365, | Nov 08 2003 | PROTHERA BIOLOGICS, INC | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
7939282, | Oct 21 2004 | Rhode Island Hospital | Methods for detecting sepsis |
9139641, | May 28 2008 | PROTHERA BIOLOGICS, INC | Preparation and composition of inter-alpha proteins from blood |
9572872, | Sep 09 2012 | PROTHERA BIOLOGICS, INC | Treatment of disease using inter-alpha inhibitor proteins |
9758570, | May 28 2008 | PROTHERA BIOLOGICS, INC | Preparation and composition of inter-alpha inhibitor proteins from blood |
20030027848, | |||
20030149062, | |||
20030190732, | |||
20040009212, | |||
20060079670, | |||
20070160594, | |||
20070172479, | |||
20070297982, | |||
20110190194, | |||
20110190208, | |||
20110236381, | |||
20110293594, | |||
20120028269, | |||
20120053113, | |||
20140206844, | |||
20150361127, | |||
CN101160133, | |||
CN1972961, | |||
EP367090, | |||
EP2664337, | |||
JP2003292459, | |||
JP200340775, | |||
JP2005531521, | |||
JP2006520390, | |||
JP2007515397, | |||
JP9503775, | |||
WO163280, | |||
WO230983, | |||
WO232406, | |||
WO3082247, | |||
WO2004082615, | |||
WO2005030252, | |||
WO2005046587, | |||
WO2005121163, | |||
WO2007038686, | |||
WO2008067655, | |||
WO2009154695, | |||
WO2010068308, | |||
WO2014039987, | |||
WO2014113659, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Oct 30 2007 | PROTHERA BIOLOGICS, LLC | PROTHERA BIOLOGICS, INC | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 051984 | /0767 | |
Apr 26 2013 | ProThera Biologics, Inc. | (assignment on the face of the patent) | / | |||
Feb 27 2020 | LIM, YOW-PIN | PROTHERA BIOLOGICS, LLC | CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED ON REEL 019118 FRAME 0124 ASSIGNOR S HEREBY CONFIRMS THE ASSIGNMENT | 052073 | /0948 | |
Feb 27 2020 | HIXSON, DOUGLAS C | PROTHERA BIOLOGICS, LLC | CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED ON REEL 019118 FRAME 0124 ASSIGNOR S HEREBY CONFIRMS THE ASSIGNMENT | 052073 | /0948 | |
Mar 01 2020 | PROTHERA BIOLOGICS, INC | The United States of America, as represented by the Secretary, Department of Health and Human Services | LICENSE SEE DOCUMENT FOR DETAILS | 052069 | /0365 | |
Mar 01 2020 | JOSIC, DJURO | PROTHERA BIOLOGICS, LLC | CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED ON REEL 019118 FRAME 0124 ASSIGNOR S HEREBY CONFIRMS THE ASSIGNMENT | 052073 | /0948 |
Date | Maintenance Fee Events |
Sep 01 2022 | BIG: Entity status set to Undiscounted (note the period is included in the code). |
Sep 20 2022 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
May 05 2023 | 4 years fee payment window open |
Nov 05 2023 | 6 months grace period start (w surcharge) |
May 05 2024 | patent expiry (for year 4) |
May 05 2026 | 2 years to revive unintentionally abandoned end. (for year 4) |
May 05 2027 | 8 years fee payment window open |
Nov 05 2027 | 6 months grace period start (w surcharge) |
May 05 2028 | patent expiry (for year 8) |
May 05 2030 | 2 years to revive unintentionally abandoned end. (for year 8) |
May 05 2031 | 12 years fee payment window open |
Nov 05 2031 | 6 months grace period start (w surcharge) |
May 05 2032 | patent expiry (for year 12) |
May 05 2034 | 2 years to revive unintentionally abandoned end. (for year 12) |